NUVATION BIO INC (NUVB:NYSE)
$5.11 -0.01 (-0.1953%)
Analysed NUVATION BIO INC (NUVB:NYSE) News Sources
Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026
21-04-2026
yahoo.com
5 Best Small-Cap Biotech Stocks According to Hedge Funds
21-04-2026
yahoo.com
Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026
20-04-2026
yahoo.com
How Much Can Nuvation Bio (NUVB) Make From Ibtrozi Sales?
17-04-2026
yahoo.com
Nuvation Bio's Ibtrozi Gains Frontline Momentum Ahead of Key Q1 Print, Wedbush Says
16-04-2026
yahoo.com
Ibtrozi Prospects Asserts Nuvation Bio Inc. (NUVB) as one of the Best Healthcare Penny Stocks
14-04-2026
yahoo.com
FDA Priority Review And New Alliances Reshape Daiichi Sankyo Growth Story
13-04-2026
yahoo.com
Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)
13-04-2026
fool.com
Wedbush Bullish on Nuvation Bio (NUVB) As NUVB Expands Safusidenib Rights
12-04-2026
yahoo.com
Nuvation Bio Inc. (NUVB) Turns Bullish amid Positive Regulatory Trajectory in Europe
06-04-2026
yahoo.com
What is the current price of NUVATION BIO INC (NUVB:NYSE)?
The current price of NUVATION BIO INC (NUVB:NYSE) is $5.11.
NUVATION BIO INC (NUVB:NYSE) absolute price change since previous trading day?
The absolute price change of NUVATION BIO INC (NUVB:NYSE) since the previous trading day is $-0.01.
NUVATION BIO INC (NUVB:NYSE) percentage price change since previous trading day?
The percentage price change of NUVATION BIO INC (NUVB:NYSE) since the previous trading day is -0.1953%.
What is the most recent average sentiment score for NUVATION BIO INC (NUVB:NYSE)?
The most recent average sentiment score for NUVATION BIO INC (NUVB:NYSE) is 91 out of 100.
What is the most recent average sentiment for NUVATION BIO INC (NUVB:NYSE)?
The most recent sentiment for NUVATION BIO INC (NUVB:NYSE) is .
SEC-8K** Filing Available For NUVATION BIO INC (NUVB:NYSE)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.